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Case Report
AbstractAdenoid Cystic Carcinoma is a rare variant of adenocarcinoma originating mainlyfrom salivary glands of the head and neck region distributed throughout the upperaerodigestive tract with a propensity for perineural invasion. Primary adenoidcystic carcinoma of lungs is exceedingly rare accounting for a mere 0.04 to 0.2percent of all pulmonary neoplasms. The existing scant case reports about this lungmalignancy mostly describe small lung lesions managed with upfront surgeryfollowed by adjuvant radiotherapy. We hereby present this case of primary lungparenchymal pathology where the disease was treated with definitivechemo-radiation and to the best of our knowledge; this case is one of the rarest andearliest reports of upfront chemo-radiation in an inoperable primary lungparenchymal ACC. A 43-year-old woman presented with complaints of cough,severe dyspnea, right sided chest pain associated with occasional hemoptysis.Radiographic imaging of thorax showed a large mass lesion with smooth marginsmeasuring 10.2 × 7.3 × 6.8 cm right lower lobe with invasion of adjacent vitalstructures. Image guided biopsy and immunohistochemical analysis confirmed thediagnosis. She was eventually treated with definitive radiotherapy with concurrentchemotherapy as she was deemed inoperable. Post therapy evaluation by imagingshowed a partial response to chemo-radiation, however there was significantsymptomatic relief. In view of CD 117 positivity, she has started on oral imatinibmesylate. Presently she is on follow up with a karnofsky performance status of90%. A thorough review of literature also reveals that our case may be the largestadenoid cystic primary parenchymal pulmonary pathology ever reported.
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1. IntroductionAdenoid cystic carcinoma (ACC) is a rare, slow growingneoplasm of major and minor salivary glands accountingfor 10% of all salivary gland tumors.1 They originatefrom secretory glands found predominantly in head andneck region like lips, oral cavity, external auditory canal,nose, orolaryngopharynx, upper aerodigestive tractlocations like esophagus, trachea and carina.2 Primarylung ACCs are very rare and account for 0.04 to 0.2% ofall lung tumors3, 4which can be central arising in trachea,main bronchus or segmental bronchi5 while peripherallung parenchymal tumors are much rarer comprising ofonly 10% of all primary lung ACCs6 as in our case.Majority of case reports recommend surgery as the firstline management of ACC lung with radiotherapy (RT)reserved for post-operative stage for local control of
disease. Upfront RT for unresectable ACC of trachea hasshown satisfactory results7 while its definitive role inprimary lung parenchymal ACC is still undefined. Sincevery less is known regarding the molecular pathwaysresponsible for the pathogenesis of pulmonary ACC,chemotherapy has a very limited role8apart from usingimatinib mesylate in c-Kit positive cases9, 10 andconcurrent carboplatin-paclitaxel with RT inunresectable tracheal ACCs.11 Faced with thistherapeutic challenge we used definitive RT withconcurrent carboplatin and paclitaxel followed by oralimatinib.
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2. Case presentationA 43-year-old female with no known comorbidities oraddictions presented with complaints of cough,progressive dyspnea, right sided chest pain withoccasional hemoptysis of 8 months duration. Chestroentgenogram showed a homogenous opacity in theright lower zone merging with mediastinum (Figure 1).Computed tomography (CT) scan of chest showed alarge well defined peripherally based heterogeneouslyenhancing mass lesion with smooth margins (Figure 2)in posterior basal segment of right lower lobe measuring7.3 × 6.0 × 10 cm extending upto right hilum encasingthe right bronchus intermedius and abutting the rightmain pulmonary artery, the inferior vena cava with lossof fat planes with right hemi-diaphragm (Figure 3).Bronchoscopy was normal and broncho-alveolar lavagedid not show any malignant cells.
Figure 1: Plain radiograph of chest showing a homogenousopacity in the right lower zone merging with mediastinum(yellow pointer).
Figure 2: CT scan chest (axial view) showing a large welldefined peripherally based heterogeneously enhancingmass lesion with smooth margins in right lower lobe oflung.
A CT guided biopsy of the lung mass showed cribriformpattern of tissue intermixed with scanty areas of normalrespiratory epithelium. The tumor cells formed nestsand tubular patterns along with mucin collection insome spaces (Figure 4). Immunohistochemistry (IHC)stained positive for CD 117 (Figure 5), smooth muscleactin (SMA), cytokeratin-7 (CK-7), epithelial membraneantigen (EMA) (Figure 6) and S-100 while negative forthyroid transcription factor-1 (TTF-1), CD-56, CD-99,neuron specific enolase (NSE), synaptophysin andchromogranin, suggesting the diagnosis of ACC lung.Positron emission tomography (PET) scan showed alocalized disease and magnetic resonance imaging (MRI)of brain was normal. Patient denied any history of oralmalignancy in past.
Figure 3: CT scan chest (coronal view) showing the mass inposterior basal segment of right lower lobe extending uptoright hilum with loss of fat planes with righthemi-diaphragm.
Figure 4: Biopsy of the lung mass showing cribriformpattern of tissue intermixed with scanty areas of normalrespiratory epithelial lining forming nests and tubularpatterns along with mucin collection in some spaces (H & E100 X).
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The patient was deemed inoperable due to involvementof adjacent vital structures where surgical resectioncould have led to high morbidity. Because of the highdisease load and aggravated symptoms she was treatedwith definitive conformal radiation therapy to a dose of60 Gray (Gy) in 30 fractions along with concurrentchemotherapy weekly Carboplatin (area under curve 2)and paclitaxel (50 mg/m2) for 6 weeks.Patient tolerated treatment well and experiencedsignificant reduction in her dyspneic episodes and coughwith improvement in exercise tolerance. Responseassessment with CT scan chest 12 weeks post combinedtherapy showed a partial response (PR) and to maintainthe PR status of the patient she was started on oralimatinib mesylate (400 mg per day), a c-KIT tyrosinekinase inhibitor. Presently on regular follow upmaintaining a Karnofsky Performance Status (KPS) of90%.
Figure 5: IHC showing CD 117/ c-Kit positivity (100 X).
Figure 6: IHC showing EMA positivity (100 X).
3. DiscussionAdenoid cystic carcinoma (ACC) is a rare malignancybelonging to the adenocarcinoma group denoting a
glandular origin arising from both minor and majorsalivary glands of head and neck, comprising 10% ofsalivary gland malignancies.1The involved sites are lips,oral cavity, hard palate, nasopharynx, external auditorycanal, oropharynx, larynx, parotids, submandibular,sublingual glands and the aerodigestive structures likeesophagus, trachea, carina, main bronchus andsegmental bronchi2while lung parenchymal tumors aremuch rarer.6 ACC are also known to arise in lacrimalglands, skin, breast, cervix and bone. ACC is known forits indolent clinical course with a propensity forperineural invasion resulting in high incidence of localrecurrence and distant metastasis to lungs followed byliver. 12Primary pulmonary ACC are extremely rare andcomprise 0.04 to 0.2% of all lung malignancies.3,4Thesecan arise from tracheobronchial glands of centralpulmonary structures like trachea, main bronchus, bothextra-pulmonary and intra-pulmonary bronchi5accounting for 0.2%13 of all lung primaries whileperipheral lung parenchymal ACCs are exceedingly rareconstituting just 10% of all pulmonary ACCs.6 The riskfactors associated with lung ACC are not known andsmoking, alcohol consumption, environmentalcarcinogen exposure, infection or any family history arenot commonly associated as compared to squamous celllung carcinomas. It is an equal opportunistic diseaseaffecting young and middle aged individuals both malesand females with a slight tilt towards the male sex intheir fourth to sixth decade of life, a decade youngerthan other lung carcinomas.2Most common presentations of lung ACCs are cough,chest pain, dyspnoea, hemoptysis, wheeze and sridor intracheal involvement. The clinical course may be slowand meandering with symptoms appearing monthsbefore a patient reports to a physician for anytroublesome complaints. Initial Imaging with chestroentgenogram, CT scans, magnetic resonance imaging(MRI) generally show intrapulmonary heterogeneouslyenhancing mass lesions often invading surroundingstructures and vital organs but do not possess thespecific features to differentiate the mass from otherlung neoplasms while PET scans and bone scans oftenform the part of a metastatic workup. In our case themass lesion on CT scan showed a smooth margin ascompared to irregular margins of squamous cellhistology.Primary lung ACC can be often be misdiagnosed with ametastatic lung lesion, mucinous adenocarcinoma orprimitive neuroectodermal tumors (PNETs) andtherefore a thorough history of tumors in other sites ofbody especially in oral cavity is of utmost importance.IHC is crucial for the exact diagnosis, however there arevery few case defining the IHC characteristics of ACClung.14,15 Hu et al.14 and Moran et al.15 reportedimmunopositivity for p63, S-100, SMA and EMA while
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immunonegative for TTF-1, CD 56, CK-20. Our casestained positive for CK-7 which favored a lung origin.TTF-1 is found predominantly in pulmonaryadenocarcinomas and thyroid, CD 56 is expressed in anyneuroendocrine tumors or PNET group of tumors whileCK-20 denotes any gastro-intestinal origin which wasnegative in our case thus ruling out other lung lesionsand establishing the diagnosis of primary ACC lung. Ourcase stained positive for CD 117, a stem cell growthfactor receptor (SCGFR) also known as proto-oncogenec-Kit or tyrosine protein kinase Kit expressed on surfaceof stem cells, mainly associated with gastrointestinalstromal tumors (GISTs), seminomas, melanomas andleukemias and ACC is also known to express high levelsof CD 117 or c-Kit.16Regarding management of ACC lung, surgical resectionremains the optimal treatment approach whereverfeasible.14 Hu et al.14 reported no overall survival benefitfor patients with R0 and R1 resection, however rate oflocal recurrence was high in R1 individuals for whichadjuvant RT was reserved for margin positive cases toreduce the rate of local recurrence and eventual distantmetastasis. Definitive RT for primary lung parenchymalACC has not been described in literature, however,unresectable tracheal entities have shown satisfactoryresults as were demonstrated by Fields et al.7The role ofchemotherapy in definitive or adjuvant setting is notproven, however, concurrent administration with RT intreating tracheal ACCs was described by Sasiaja et al.17 ,Videtic et al.18 and Aaron et al.11 using carboplatin andpaclitaxel chemo-regime in management of trachealACCs with good result.11,17,18 Based on these facts weused upfront RT to a dose of 60 Gy with concurrentcarboplatin-paclitaxel regime to which our caseresponded well, though with a radiological PR but withexcellent symptomatic response. Imatinib mesylate, ac-Kit tyrosine kinase inhibitor (TKI) is used  againstACC of salivary glands9, 10 but not for lung pathology.Since our patient was positive for c-kit, we used oralimatinib to maintain the PR status with significantresponse. The use of Sorafenib, a novel TKI has showngood response in metastatic ACC to lungs.19
4. ConclusionBy reporting this case, we recommend that the diagnosisof ACC lung should always be considered in patientspresenting with cough and dyspnoea showing apulmonary parenchymal mass on imaging. Presentlythere are no definite therapeutic guidelines for thisdisease entity as most information is based on solitarycase reports and small case series. Apart from 3-DCRT,highly conformal techniques like intensity modulatedradiotherapy (IMRT) and proton therapy can be used toprescribe higher radiation dosage without normal tissuetoxicity. We also emphasize the need for clinical trialsand better understanding of the molecular and biologicpathways involved in its pathogenesis with development
of novel chemotherapeutic drugs acting against thispulmonary pathology to improve the disease free andoverall survival.
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